Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 14/20 | 0.65 |
| ▸ | BRD1 | O95696 | 10/20 | 0.65 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.65 |
| ▸ | BRD4 | O60885 | 4/20 | 0.65 |
| ▸ | BRPF3 | Q9ULD4 | 6/20 | 0.59 |
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13742709 | 0.83 | BRPF1 (0.71) | BRPF1BRD1BRD9BRD4BRPF3 | |
| SCHEMBL12050293 | 0.81 | BRPF1 (0.67) | BRPF1BRD1BRD9BRD4BRPF3 | |
| SCHEMBL6022235 | 0.80 | TAS2R14 (0.47) | BRPF1BRD1BRD9BRD4PKM | |
| SCHEMBL17560706 | 0.80 | BRPF1 (0.67) | BRPF1BRD1BRD9BRD4BRPF3 | |
| SCHEMBL4193118 | 0.77 | BRPF1 (0.51) | BRPF1BRD1BRD9BRD4BRPF3 | |
| SCHEMBL4193183 | 0.77 | BRPF1 (0.50) | BRPF1BRD1BRD9BRD4BRPF3 | |
| SCHEMBL4192303 | 0.77 | BRPF1 (0.50) | BRPF1BRD1BRD9BRD4BRPF3 | |
| SCHEMBL19435605 | 0.74 | BRPF1 (1.00) | BRPF1BRD1BRD9BRD4BRPF3 | |
| SCHEMBL9329231 | 0.74 | PTGES2 (0.51) | ALDH1A1POLBLMNA | |
| SCHEMBL31083427 | 0.72 | LMNA (0.64) | PKMALDH1A1POLBSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215764-A1 | Antimicrobial agents | TUFM, RPS17, HARS1 | BRPF1 3456/4885BRD1 1986/4885BRD9 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.